[go: up one dir, main page]

JP2008007461A - Method for producing halogen-containing phenylalanine derivative - Google Patents

Method for producing halogen-containing phenylalanine derivative Download PDF

Info

Publication number
JP2008007461A
JP2008007461A JP2006179753A JP2006179753A JP2008007461A JP 2008007461 A JP2008007461 A JP 2008007461A JP 2006179753 A JP2006179753 A JP 2006179753A JP 2006179753 A JP2006179753 A JP 2006179753A JP 2008007461 A JP2008007461 A JP 2008007461A
Authority
JP
Japan
Prior art keywords
general formula
halogen
butyl
tert
diphenylimino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006179753A
Other languages
Japanese (ja)
Inventor
Takumi Kagawa
巧 香川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tosoh Corp
Original Assignee
Tosoh Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tosoh Corp filed Critical Tosoh Corp
Priority to JP2006179753A priority Critical patent/JP2008007461A/en
Publication of JP2008007461A publication Critical patent/JP2008007461A/en
Pending legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

【課題】 工業的に有用な、ハロゲン含有フェニルアラニン誘導体の製造方法を提供する。
【解決手段】 下記式(1)で示されるイミノグリシン誘導体を、スピロ型キラル相間移動触媒存在下、ハロゲン含有ベンジルブロミド誘導体と反応を行い、ハロゲン含有フェニルアラニン誘導体を得る。

Figure 2008007461

【選択図】なしPROBLEM TO BE SOLVED: To provide an industrially useful method for producing a halogen-containing phenylalanine derivative.
The iminoglycine derivative represented by the following formula (1) is reacted with a halogen-containing benzyl bromide derivative in the presence of a spiro-type chiral phase transfer catalyst to obtain a halogen-containing phenylalanine derivative.
Figure 2008007461

[Selection figure] None

Description

本発明はハロゲン含有フェニルアラニン誘導体の製造方法に関する。ハロゲン含有アミノ酸類は医薬品の合成中間体として期待される化合物である。   The present invention relates to a method for producing a halogen-containing phenylalanine derivative. Halogen-containing amino acids are expected compounds as synthetic intermediates for pharmaceuticals.

本発明の化合物は知られていない。本発明に関連するキラル相間移動触媒を用いたアミノ酸類の合成方法としては、例えば、下記一般式(9)   The compounds of the present invention are not known. As a method for synthesizing amino acids using a chiral phase transfer catalyst related to the present invention, for example, the following general formula (9)

Figure 2008007461
Figure 2008007461

で示される光学活性スピロ型四級アンモニウム塩において、
=水素原子、X=臭化物イオンである化合物(A)、
=フェニル基、X=臭化物イオンである化合物(B)、
=3,5−ビス(トリフルオロメチル)フェニル基、X=臭化物イオンである化合物(C)
等が知られており、同触媒を用いた光学活性フェニルアラニン誘導体の製造法が知られている。[特許文献1、非特許文献1参照]。
In the optically active spiro quaternary ammonium salt represented by
Compound (A) wherein R 1 = hydrogen atom, X = bromide ion,
Compound (B) wherein R 1 = phenyl group, X = bromide ion,
Compound (C) wherein R 1 = 3,5-bis (trifluoromethyl) phenyl group, X = bromide ion
And the like, and a method for producing an optically active phenylalanine derivative using the same catalyst is known. [See Patent Document 1 and Non-Patent Document 1].

また、光学選択性の向上のため、性能が改善された下記一般式(10)   Further, the following general formula (10) whose performance has been improved to improve optical selectivity:

Figure 2008007461
Figure 2008007461

(上記式中、Rは3,5−ジフェニルフェニル、Xが臭素イオンを表す。)
で示される触媒を用いた光学活性フェニルアラニン誘導体の製造法が知られている[特許文献2参照]。
(In the above formula, R 1 represents 3,5-diphenylphenyl, and X represents a bromine ion.)
A method for producing an optically active phenylalanine derivative using a catalyst represented by the formula [2] is known [see Patent Document 2].

特開2001−48866号公報JP 2001-48866 A 特開2002−326992号公報JP 2002-326992 A K.Maruoka et. al. Angew.Chem.Int.Ed.,2003,42(5),579K. Maruoka et. al. Angew. Chem. Int. Ed. , 2003, 42 (5), 579

従来の触媒を用いた場合、後述する式(1)で示されるイミノグリシン誘導体のベンジル化において満足できる光学選択性を与える触媒はあるものの、触媒の製造工程が長く、複雑で高価な触媒となり、工業的に利用可能な製法ということができなかった。   In the case of using a conventional catalyst, although there are catalysts that give satisfactory optical selectivity in benzylation of an iminoglycine derivative represented by the formula (1) described later, the catalyst production process is long and becomes a complicated and expensive catalyst. It could not be an industrially usable production method.

一方、核がハロゲンで置換されたフェニルアラニン誘導体は公知であるが、キラル相間移動触媒を用いて、高い光学選択性で製造する方法は知られていなかった。   On the other hand, phenylalanine derivatives in which the nucleus is substituted with halogen are known, but a method for producing them with high optical selectivity using a chiral phase transfer catalyst has not been known.

さらに従来の触媒では、ベンジルブロミドの2位が置換されたベンジルブロミド誘導体を用い、2−が置換されたフェニルアラニン誘導体の製法は知られていなかった。   Furthermore, in the conventional catalyst, the manufacturing method of the phenylalanine derivative substituted with 2- using the benzyl bromide derivative substituted by 2-position of benzyl bromide was not known.

本発明は上記の課題に鑑みてなされたものであり、その目的は、核の2−位、3−位、又は4−位のいずれかの位置がハロゲン又はハロゲン含有アルキルで置換されたフェニルアラニン誘導体を、高収率、高選択性で工業的に製造する方法を提供することである。   The present invention has been made in view of the above problems, and the purpose thereof is a phenylalanine derivative in which any one of the 2-position, 3-position, and 4-position of the nucleus is substituted with halogen or halogen-containing alkyl. Is to be industrially produced with high yield and high selectivity.

本発明者は、上記課題を解決するため鋭意検討した結果、後述する一般式(3)又は一般式(5)で示される合成が容易なスピロ型キラル相間移動触媒を用い、高収率、高選択性でフェニル環上の2−位、3−位、又は4−位のいずれかの場所がハロゲン又はハロゲン含有アルキル基で置換されたフェニルアラニン誘導体が製造可能であることを見出し、本発明を完成させるに至った。   As a result of intensive studies to solve the above problems, the present inventor has used a spiro-type chiral phase transfer catalyst that can be easily synthesized as shown in the following general formula (3) or general formula (5). The inventors have found that a phenylalanine derivative in which the 2-position, 3-position, or 4-position on the phenyl ring is substituted with a halogen or a halogen-containing alkyl group can be produced, and the present invention is completed. I came to let you.

すなわち本発明は、以下に示すとおりのハロゲン含有フェニルアラニン誘導体の製造方法である。   That is, the present invention is a method for producing a halogen-containing phenylalanine derivative as shown below.

[1]下記式(1)   [1] The following formula (1)

Figure 2008007461
Figure 2008007461

で示されるジフェニルイミノグリシン誘導体と、下記一般式(2) And a diphenyliminoglycine derivative represented by the following general formula (2):

Figure 2008007461
Figure 2008007461

[上記一般式(2)中、Rはハロゲン原子、又はハロゲン原子で置換された炭素数1〜4の直鎖若しくは分岐のアルキル基を示す。]
で示されるベンジルブロミド誘導体を、下記式(3)
[In the general formula (2), R represents a halogen atom or a linear or branched alkyl group having 1 to 4 carbon atoms substituted with a halogen atom. ]
A benzyl bromide derivative represented by the following formula (3)

Figure 2008007461
Figure 2008007461

で示されるキラル相間移動触媒及びアルカリの存在下反応させることを特徴とする下記一般式(4) The reaction is carried out in the presence of a chiral phase transfer catalyst represented by the following general formula (4):

Figure 2008007461
Figure 2008007461

[上記一般式(4)中、Rはハロゲン原子、又はハロゲン原子で置換された炭素数1〜4の直鎖若しくは分岐のアルキル基を示す。]
で示されるハロゲン含有フェニルアラニン誘導体の製造方法。
[In the general formula (4), R represents a halogen atom or a linear or branched alkyl group having 1 to 4 carbon atoms substituted with a halogen atom. ]
The manufacturing method of the halogen-containing phenylalanine derivative shown by these.

[2]上記式(1)で示されるジフェニルイミノグリシン誘導体と、上記一般式(2)で示されるベンジルブロミド誘導体を、下記式(5)   [2] A diphenyliminoglycine derivative represented by the above formula (1) and a benzyl bromide derivative represented by the above general formula (2) are represented by the following formula (5)

Figure 2008007461
Figure 2008007461

で示されるキラル相間移動触媒及びアルカリの存在下反応させることを特徴とする一般式(6) The reaction is carried out in the presence of a chiral phase transfer catalyst represented by the formula (6)

Figure 2008007461
Figure 2008007461

[上記一般式(6)中、Rはハロゲン原子、又はハロゲン原子で置換された炭素数1〜4の直鎖若しくは分岐のアルキル基を示す。]
で示されるハロゲン含有フェニルアラニン誘導体の製造方法。
[In the general formula (6), R represents a halogen atom or a linear or branched alkyl group having 1 to 4 carbon atoms substituted with a halogen atom. ]
The manufacturing method of the halogen-containing phenylalanine derivative shown by these.

[3]上記一般式(4)で示されるハロゲン含有フェニルアラニン誘導体を酸の存在下、加水分解することを特徴とする下記一般式(7)   [3] A halogen-containing phenylalanine derivative represented by the above general formula (4) is hydrolyzed in the presence of an acid, and the following general formula (7)

Figure 2008007461
Figure 2008007461

[上記一般式(7)中、Rはハロゲン原子、又はハロゲン原子で置換された炭素数1〜4の直鎖若しくは分岐のアルキル基を示す。]
で示されるハロゲン含有フェニルアラニンの製造方法。
[In the general formula (7), R represents a halogen atom or a linear or branched alkyl group having 1 to 4 carbon atoms substituted with a halogen atom. ]
The manufacturing method of halogen-containing phenylalanine shown by these.

[4]上記一般式(6)で示されるハロゲン含有フェニルアラニン誘導体を酸で存在下、加水分解することを特徴とする下記一般式(8)   [4] A halogen-containing phenylalanine derivative represented by the general formula (6) is hydrolyzed in the presence of an acid, and the following general formula (8)

Figure 2008007461
Figure 2008007461

[上記一般式(8)中、Rはハロゲン原子、又はハロゲン原子で置換された炭素数1〜4の直鎖若しくは分岐のアルキル基を示す。]
で示されるハロゲン含有フェニルアラニンの製造方法。
[In the general formula (8), R represents a halogen atom or a linear or branched alkyl group having 1 to 4 carbon atoms substituted with a halogen atom. ]
The manufacturing method of halogen-containing phenylalanine shown by these.

本発明によれば、核の2−位、3−位、又は4−位のいずれかの位置がハロゲン又はハロゲン含有アルキルで置換されたフェニルアラニン誘導体を、高収率、高選択性で工業的に製造することができる。   According to the present invention, a phenylalanine derivative in which any one of the 2-position, 3-position, and 4-position of the nucleus is substituted with halogen or halogen-containing alkyl is industrially produced with high yield and high selectivity. Can be manufactured.

含フッ素異常アミノ酸類は医薬品の合成原料として有用な化合物であり、本発明は工業上極めて有意義である。   Fluorine-containing abnormal amino acids are compounds useful as synthetic raw materials for pharmaceuticals, and the present invention is extremely significant industrially.

以下、本発明を詳細に説明する。   Hereinafter, the present invention will be described in detail.

本発明の上記式(1)で示されるイミノグリシン誘導体はtert−ブチル 2−アミノアセテート・塩酸塩(グリシン tert−ブチルエステル・塩酸塩)とベンゾフェノンイミン及びトリエチルアミンの反応で用意に調製できる。   The iminoglycine derivative represented by the above formula (1) of the present invention can be prepared in advance by a reaction of tert-butyl 2-aminoacetate / hydrochloride (glycine tert-butyl ester / hydrochloride), benzophenone imine and triethylamine.

本発明に適用可能なベンジルブロミド誘導体としては、上記一般式(2)で示されるベンジルブロミド誘導体であればよく、特に限定するものではないが、具体的には、2−フルオロベンジルブロミド、3−フルオロベンジルブロミド、4−フルオロベンジルブロミド、2−クロロベンジルブロミド、3−クロロベンジルブロミド、4−クロロベンジルブロミド、2−ブロモベンジルブロミド、3−ブロモベンジルブロミド、4−ブロモベンジルブロミド、2−ヨウドベンジルブロミド、3−ヨウドベンジルブロミド、4−ヨウドベンジルブロミド、2−トリフルオロメチルベンジルブロミド、3−トリフルオロメチルベンジルブロミド、4−トリフルオロメチルベンジルブロミド、2−(2,2,2−トリフルオロエチル)ベンジルブロミド、3−(2,2,2−トリフルオロエチル)ベンジルブロミド、4−(2,2,2−トリフルオロエチル)ベンジルブロミド、2−ペンタフルオロエチルベンジルブロミド、3−ペンタフルオロエチルベンジルブロミド、4−ペンタフルオロエチルベンジルブロミド等が例示される。   The benzyl bromide derivative applicable to the present invention is not particularly limited as long as it is a benzyl bromide derivative represented by the above general formula (2). Specifically, 2-fluorobenzyl bromide, 3- Fluorobenzyl bromide, 4-fluorobenzyl bromide, 2-chlorobenzyl bromide, 3-chlorobenzyl bromide, 4-chlorobenzyl bromide, 2-bromobenzyl bromide, 3-bromobenzyl bromide, 4-bromobenzyl bromide, 2-iodobenzyl Bromide, 3-iodobenzyl bromide, 4-iodobenzyl bromide, 2-trifluoromethylbenzyl bromide, 3-trifluoromethylbenzyl bromide, 4-trifluoromethylbenzyl bromide, 2- (2,2,2-trifluoroethyl) ) Benzyl bromi 3- (2,2,2-trifluoroethyl) benzyl bromide, 4- (2,2,2-trifluoroethyl) benzyl bromide, 2-pentafluoroethylbenzyl bromide, 3-pentafluoroethylbenzyl bromide, 4 -Pentafluoroethylbenzyl bromide and the like are exemplified.

本発明の製造方法で得られる上記一般式(4)で示されるハロゲン含有フェニルアラニン誘導体としては特に限定するものではないが、具体的には、tert−ブチル (R)−2−ジフェニルイミノ−(2−フルオロフェニル)ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−(3−フルオロフェニル)ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−(4−フルオロフェニル)ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−(2−クロロフェニル)ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−(3−クロロフェニル)ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−(4−クロロフェニル)ブチレート、(R)−2−ジフェニルイミノ−(2−ブロモフェニル)ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−(3−ブロモフェニル)ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−(4−ブロモフェニル)ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−(2−ヨウドフェニル)ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−(3−ヨウドフェニル)ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−(4−ヨウドフェニル)ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−(2−トリフルオロメチルフェニル)ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−(3−トリフルオロメチルフェニル)ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−(4−トリフルオロメチルフェニル)ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−[2−(2,2,2−トリフルオロエチル)フェニル]ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−[3−(2,2,2−トリフルオロエチル)フェニル]ブチレート、tert−ブチル (R)−2−ジフェニルイミノ−[4−(2,2,2−トリフルオロエチル)フェニル]ブチレート等が例示される。   Although it does not specifically limit as a halogen-containing phenylalanine derivative shown by the said General formula (4) obtained with the manufacturing method of this invention, Specifically, tert- butyl (R) -2-diphenylimino- (2 -Fluorophenyl) butyrate, tert-butyl (R) -2-diphenylimino- (3-fluorophenyl) butyrate, tert-butyl (R) -2-diphenylimino- (4-fluorophenyl) butyrate, tert-butyl ( R) -2-diphenylimino- (2-chlorophenyl) butyrate, tert-butyl (R) -2-diphenylimino- (3-chlorophenyl) butyrate, tert-butyl (R) -2-diphenylimino- (4-chlorophenyl) ) Butyrate, (R) -2-diphenylimino- (2-butyl) Mophenyl) butyrate, tert-butyl (R) -2-diphenylimino- (3-bromophenyl) butyrate, tert-butyl (R) -2-diphenylimino- (4-bromophenyl) butyrate, tert-butyl (R) 2-diphenylimino- (2-iodophenyl) butyrate, tert-butyl (R) -2-diphenylimino- (3-iodophenyl) butyrate, tert-butyl (R) -2-diphenylimino- (4-iodo Phenyl) butyrate, tert-butyl (R) -2-diphenylimino- (2-trifluoromethylphenyl) butyrate, tert-butyl (R) -2-diphenylimino- (3-trifluoromethylphenyl) butyrate, tert- Butyl (R) -2-diphenylimino- 4-trifluoromethylphenyl) butyrate, tert-butyl (R) -2-diphenylimino- [2- (2,2,2-trifluoroethyl) phenyl] butyrate, tert-butyl (R) -2-diphenylimino -[3- (2,2,2-trifluoroethyl) phenyl] butyrate, tert-butyl (R) -2-diphenylimino- [4- (2,2,2-trifluoroethyl) phenyl] butyrate and the like Illustrated.

本発明の製造方法で得られる上記一般式(6)で示されるハロゲン含有フェニルアラニン誘導体としては、特に限定するものではないが、tert−ブチル (S)−2−ジフェニルイミノ−(2−フルオロフェニル)ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−(3−フルオロフェニル)ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−(4−フルオロフェニル)ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−(2−クロロフェニル)ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−(3−クロロフェニル)ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−(4−クロロフェニル)ブチレート、(S)−2−ジフェニルイミノ−(2−ブロモフェニル)ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−(3−ブロモフェニル)ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−(4−ブロモフェニル)ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−(2−ヨウドフェニル)ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−(3−ヨウドフェニル)ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−(4−ヨウドフェニル)ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−(2−トリフルオロメチルフェニル)ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−(3−トリフルオロメチルフェニル)ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−(4−トリフルオロメチルフェニル)ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−[2−(2,2,2−トリフルオロエチル)フェニル]ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−[3−(2,2,2−トリフルオロエチル)フェニル]ブチレート、tert−ブチル (S)−2−ジフェニルイミノ−[4−(2,2,2−トリフルオロエチル)フェニル]ブチレート等が例示される。   The halogen-containing phenylalanine derivative represented by the general formula (6) obtained by the production method of the present invention is not particularly limited, but tert-butyl (S) -2-diphenylimino- (2-fluorophenyl) Butyrate, tert-butyl (S) -2-diphenylimino- (3-fluorophenyl) butyrate, tert-butyl (S) -2-diphenylimino- (4-fluorophenyl) butyrate, tert-butyl (S) -2 -Diphenylimino- (2-chlorophenyl) butyrate, tert-butyl (S) -2-diphenylimino- (3-chlorophenyl) butyrate, tert-butyl (S) -2-diphenylimino- (4-chlorophenyl) butyrate, ( S) -2-Diphenylimino- (2-bromopheny ) Butyrate, tert-butyl (S) -2-diphenylimino- (3-bromophenyl) butyrate, tert-butyl (S) -2-diphenylimino- (4-bromophenyl) butyrate, tert-butyl (S)- 2-diphenylimino- (2-iodophenyl) butyrate, tert-butyl (S) -2-diphenylimino- (3-iodophenyl) butyrate, tert-butyl (S) -2-diphenylimino- (4-iodophenyl) ) Butyrate, tert-butyl (S) -2-diphenylimino- (2-trifluoromethylphenyl) butyrate, tert-butyl (S) -2-diphenylimino- (3-trifluoromethylphenyl) butyrate, tert-butyl (S) -2-diphenylimino- (4-tri Fluoromethylphenyl) butyrate, tert-butyl (S) -2-diphenylimino- [2- (2,2,2-trifluoroethyl) phenyl] butyrate, tert-butyl (S) -2-diphenylimino- [ Examples include 3- (2,2,2-trifluoroethyl) phenyl] butyrate, tert-butyl (S) -2-diphenylimino- [4- (2,2,2-trifluoroethyl) phenyl] butyrate, and the like. The

本発明の上記式(3)又は式(5)で示されるキラル相間移動触媒は、例えば、特開2005−41791号公報に記載の方法により、光学活性(S)−1,1’−ビ−2−ナフトール又は(R)−1,1’−ビ−2−ナフトールを原料とし、11反応で調製することができる。   The chiral phase transfer catalyst represented by the above formula (3) or formula (5) of the present invention is optically active (S) -1,1′-bi-by, for example, the method described in JP-A-2005-41791. It can be prepared by 11 reactions using 2-naphthol or (R) -1,1′-bi-2-naphthol as a raw material.

本発明の上記式(3)又は式(4)で示されるキラル相間移動触媒の使用量は、反応に具する上記式(1)で示されるイミノグリシン誘導体に対して、0.03モル%〜5モル%の範囲で、好ましくは0.05モル%〜2モル%の範囲である。   The amount of the chiral phase transfer catalyst represented by the above formula (3) or formula (4) of the present invention is 0.03 mol% to the iminoglycine derivative represented by the above formula (1) included in the reaction. It is in the range of 5 mol%, preferably in the range of 0.05 mol% to 2 mol%.

本発明の上記一般式(4)又は一般式(6)で示される化合物を得る反応に適用可能な溶剤としては、反応に不活性な溶剤であればあらゆるものが適用可能であるが、好ましくはトルエン、ベンゼン、エチルベンゼン、メシチレン等の芳香族炭化水素類、ジエチルエーテル、THF等のエーテル類等が例示される。   As the solvent applicable to the reaction for obtaining the compound represented by the general formula (4) or the general formula (6) of the present invention, any solvent can be used as long as it is inert to the reaction. Examples include aromatic hydrocarbons such as toluene, benzene, ethylbenzene, and mesitylene, and ethers such as diethyl ether and THF.

本発明の上記一般式(4)又は一般式(6)で示される化合物を得る反応に適用可能な溶剤の使用量としては、反応に用いる上記式(5)で示されるtert−ブチル 4,4,4−トリフルオロ−2−(4−クロロフェニル)イミノブチレートに対して、3重量倍量〜200重量倍量の範囲で使用可能であるが好ましくは5重量倍量〜100重量倍量の範囲である。   The amount of the solvent applicable to the reaction for obtaining the compound represented by the general formula (4) or the general formula (6) of the present invention is tert-butyl 4,4 represented by the above formula (5) used for the reaction. , 4-trifluoro-2- (4-chlorophenyl) iminobutyrate can be used in the range of 3 to 200 times by weight, but preferably in the range of 5 to 100 times by weight. It is.

本発明の上記一般式(4)又は一般式(6)で示される化合物を得る反応に適用可能なアルカリとしては、水酸化リチウム、水酸化ナトリウム、水酸化カリウム、水酸化ルビジウム、水酸化セシウム、水酸化セシウム・1水和物等が好適なものとして例示され、反応に用いる上記式(1)で示されるイミノグリシン誘導体に対して、通常1モル量〜30モル量使用する。アルカリの添加方法としては、反応に用いる溶剤に溶解させて使用しても良いし、粉末を添加しても良く、さらに水溶液を用いても良い。   Examples of the alkali applicable to the reaction for obtaining the compound represented by the general formula (4) or the general formula (6) of the present invention include lithium hydroxide, sodium hydroxide, potassium hydroxide, rubidium hydroxide, cesium hydroxide, Cesium hydroxide monohydrate is exemplified as a suitable example, and it is usually used in an amount of 1 to 30 mol with respect to the iminoglycine derivative represented by the above formula (1) used in the reaction. As an alkali addition method, it may be used by dissolving in a solvent used for the reaction, a powder may be added, or an aqueous solution may be used.

本発明の上記一般式(4)又は一般式(6)で示される化合物を得る反応の反応温度としては通常0℃〜−20℃の範囲、反応時間としては通常15分〜24時間の範囲である。   The reaction temperature for obtaining the compound represented by the general formula (4) or general formula (6) of the present invention is usually in the range of 0 ° C. to −20 ° C., and the reaction time is usually in the range of 15 minutes to 24 hours. is there.

本発明の上記一般式(4)又は一般式(6)で示される化合物を得る反応の終了後、例えば、飽和の重曹水溶液で洗浄、硫酸マグネシウムで乾燥、ろ過、濃縮することにより上記一般式(4)又は一般式(6)で示される目的物を得る。また、必要に応じて、シリカゲルカラム等により精製を行っても良い。   After completion of the reaction for obtaining the compound represented by the above general formula (4) or general formula (6) of the present invention, for example, washing with a saturated aqueous sodium bicarbonate solution, drying over magnesium sulfate, filtration and concentration, the above general formula ( 4) or the target product represented by the general formula (6) is obtained. Moreover, you may refine | purify with a silica gel column etc. as needed.

上記一般式(7)で示されるハロゲン含有フェニルアラニンとしては、特に限定するものではないが、具体的には、(R)−(2−フルオロフェニル)アラニン、(R)−(3−フルオロフェニル)アラニン、(R)−(4−フルオロフェニル)アラニン、(R)−(2−クロロフェニル)アラニン、(R)−(3−クロロフェニル)アラニン、(R)−(4−クロロフェニル)アラニン、(R)−(2−ブロモフェニル)アラニン、(R)−(3−ブロモフェニル)アラニン、(R)−(4−ブロモフェニル)アラニン、(R)−(2−ヨウドフェニル)アラニン、(R)−(3−ヨウドフェニル)アラニン、(R)−(4−ヨウドフェニル)アラニン、(R)−(2−トリフルオロメチルフェニル)アラニン、(R)−(3−トリフルオロメチルフェニル)アラニン、(R)−(4−トリフルオロメチルフェニル)アラニン、(R)−[2−(2,2,2−トリフルオロエチル)フェニル]アラニン、(R)−[3−(2,2,2−トリフルオロエチル)フェニル]アラニン、(R)−[4−(2,2,2−トリフルオロエチル)フェニル]アラニン等が例示される。   The halogen-containing phenylalanine represented by the general formula (7) is not particularly limited, and specifically, (R)-(2-fluorophenyl) alanine, (R)-(3-fluorophenyl) Alanine, (R)-(4-fluorophenyl) alanine, (R)-(2-chlorophenyl) alanine, (R)-(3-chlorophenyl) alanine, (R)-(4-chlorophenyl) alanine, (R) -(2-bromophenyl) alanine, (R)-(3-bromophenyl) alanine, (R)-(4-bromophenyl) alanine, (R)-(2-iodophenyl) alanine, (R)-( 3-iodophenyl) alanine, (R)-(4-iodophenyl) alanine, (R)-(2-trifluoromethylphenyl) alanine, (R)-(3-trifluoro) Methylphenyl) alanine, (R)-(4-trifluoromethylphenyl) alanine, (R)-[2- (2,2,2-trifluoroethyl) phenyl] alanine, (R)-[3- (2 , 2,2-trifluoroethyl) phenyl] alanine, (R)-[4- (2,2,2-trifluoroethyl) phenyl] alanine and the like.

また、上記一般式(8)で示されるハロゲン含有フェニルアラニンとしては、特に限定するものではないが、(S)−(2−フルオロフェニル)アラニン、(S)−(3−フルオロフェニル)アラニン、(S)−(4−フルオロフェニル)アラニン、(S)−(2−クロロフェニル)アラニン、(S)−(3−クロロフェニル)アラニン、(S)−(4−クロロフェニル)アラニン、(S)−(2−ブロモフェニル)アラニン、(S)−(3−ブロモフェニル)アラニン、(S)−(4−ブロモフェニル)アラニン、(S)−(2−ヨウドフェニル)アラニン、(S)−(3−ヨウドフェニル)アラニン、(S)−(4−ヨウドフェニル)アラニン、(S)−(2−トリフルオロメチルフェニル)アラニン、(S)−(3−トリフルオロメチルフェニル)アラニン、(S)−(4−トリフルオロメチルフェニル)アラニン、(S)−[2−(2,2,2−トリフルオロエチル)フェニル]アラニン、(S)−[3−(2,2,2−トリフルオロエチル)フェニル]アラニン、(S)−[4−(2,2,2−トリフルオロエチル)フェニル]アラニン等が例示される。   The halogen-containing phenylalanine represented by the general formula (8) is not particularly limited, but (S)-(2-fluorophenyl) alanine, (S)-(3-fluorophenyl) alanine, ( S)-(4-fluorophenyl) alanine, (S)-(2-chlorophenyl) alanine, (S)-(3-chlorophenyl) alanine, (S)-(4-chlorophenyl) alanine, (S)-(2 -Bromophenyl) alanine, (S)-(3-bromophenyl) alanine, (S)-(4-bromophenyl) alanine, (S)-(2-iodophenyl) alanine, (S)-(3-iodo) Phenyl) alanine, (S)-(4-iodophenyl) alanine, (S)-(2-trifluoromethylphenyl) alanine, (S)-(3-trifluoromethyl) Phenyl) alanine, (S)-(4-trifluoromethylphenyl) alanine, (S)-[2- (2,2,2-trifluoroethyl) phenyl] alanine, (S)-[3- (2, Examples include 2,2-trifluoroethyl) phenyl] alanine, (S)-[4- (2,2,2-trifluoroethyl) phenyl] alanine, and the like.

本発明の上記一般式(7)又は一般式(8)で示されるハロゲン含有フェニルアラニンを得る方法としては、特に限定するものではないが、例えば、3〜12Nの塩酸水溶液中又は5〜30%の硫酸水溶液中、0℃〜60℃で1〜24時間反応することにより得られる。また、必要に応じてメタノール、THF等の有機溶剤を用いても良い。基質濃度としては、溶剤全量に対して通常1〜50重量%の範囲で実施可能である。   The method for obtaining the halogen-containing phenylalanine represented by the general formula (7) or the general formula (8) of the present invention is not particularly limited. For example, in a 3-12N hydrochloric acid aqueous solution or 5-30% It can be obtained by reacting in an aqueous sulfuric acid solution at 0 to 60 ° C. for 1 to 24 hours. Moreover, you may use organic solvents, such as methanol and THF, as needed. The substrate concentration can be generally in the range of 1 to 50% by weight with respect to the total amount of the solvent.

以下実施例により本発明を具体的に説明するが、本発明はこれらの実施例のみに限定されるものではない。   EXAMPLES The present invention will be specifically described below with reference to examples, but the present invention is not limited only to these examples.

調製例1 tert−ブチル 2−ジフェニルイミノアセテートの調製
滴下ロート及び攪拌子を備えた500mlの3つ口丸底フラスコにtert−ブチル 2−アミノアセテート・塩酸塩(グリシン tert−ブチルエステル・塩酸塩、10.0g、59.7mmol)、ベンゾフェノンイミン(10.81g、59.7mmol)、及びジクロロメタン(265g)を仕込み室温下、24時間攪拌した。
Preparation Example 1 Preparation of tert-butyl 2-diphenyliminoacetate In a 500 ml three-necked round bottom flask equipped with a dropping funnel and a stirrer, tert-butyl 2-aminoacetate hydrochloride (glycine tert-butyl ester hydrochloride) 10.0 g, 59.7 mmol), benzophenone imine (10.81 g, 59.7 mmol), and dichloromethane (265 g) were charged and stirred at room temperature for 24 hours.

反応終了後、ろ過し、ろ液を濃縮、40℃で減圧乾燥し、ジエチルエーテル(200ml)に溶解、水(200ml×2回)で洗浄、硫酸マグネシウム(10g)で乾燥、ろ過、濃縮、減圧乾燥することにより目的物のtert−ブチル 2−ジフェニルイミノアセテート(18.02g、59.7mmol)を無色固体として得た(収率:>99%)。   After completion of the reaction, the mixture was filtered, and the filtrate was concentrated and dried under reduced pressure at 40 ° C., dissolved in diethyl ether (200 ml), washed with water (200 ml × 2 times), dried over magnesium sulfate (10 g), filtered, concentrated and reduced pressure. By drying, the target tert-butyl 2-diphenyliminoacetate (18.02 g, 59.7 mmol) was obtained as a colorless solid (yield:> 99%).

実施例1 tert−ブチル (R)−2−ジフェニルイミノ−(2−フルオロフェニル)ブチレートの調製
攪拌子を備えた50mlのナス型フラスコに調製例1で調製したtert−ブチル 2−ジフェニルイミノアセテート(300mg,1.02mmol)、スピロビス[{(S)−1,1′−ビ−{4,6−ビス(オクチルジメチルシリル)ナフチル}}−2,2′−ジメチル]アンモニウムブロミド(10.2mg,0.0051mmol)及びトルエン(10ml)を仕込み攪拌しながら0℃に冷却した。次いで、これに2−フルオロベンジルブロミド(230mg,1.22mmol)を添加し、さらに50%水酸化カリウム水溶液(2.40g,30.6mmol)を添加し、同温度で24時間反応を行った。
Example 1 Preparation of tert-butyl (R) -2-diphenylimino- (2-fluorophenyl) butyrate The tert-butyl 2-diphenyliminoacetate prepared in Preparation Example 1 in a 50 ml eggplant-shaped flask equipped with a stirrer ( 300 mg, 1.02 mmol), spirobis [{(S) -1,1′-bi- {4,6-bis (octyldimethylsilyl) naphthyl}}-2,2′-dimethyl] ammonium bromide (10.2 mg, 0.0051 mmol) and toluene (10 ml) were charged and cooled to 0 ° C. with stirring. Next, 2-fluorobenzyl bromide (230 mg, 1.22 mmol) was added thereto, 50% aqueous potassium hydroxide solution (2.40 g, 30.6 mmol) was further added, and the reaction was performed at the same temperature for 24 hours.

反応終了後、飽和の塩化アンモニウム水溶液(10ml)を添加し、分液の後、水層をジクロロメタン(5ml×2回)抽出、有機層を合わせて、硫酸ナトリウム上で乾燥、ろ過、濃縮し粗製の目的物を得、シリカゲルカラムクロマトグラフィー(ヘキサン/酢酸エチル=80/10 vol/vol)で精製することにより目的物のtert−ブチル (R)−2−ジフェニルイミノ−(2−フルオロフェニル)ブチレート(405mg、1.05mmol)を無色のオイルとして得た(収率:>99%)。ダイセル社製キラルカラムAD−H(ヘキサン/イソプロパノール=9/1 vol/vol)を用いた測定において、光学純度は98.5%eeであった。   After completion of the reaction, a saturated aqueous ammonium chloride solution (10 ml) was added, and after separation, the aqueous layer was extracted with dichloromethane (5 ml × 2 times), and the organic layers were combined, dried over sodium sulfate, filtered and concentrated to give a crude product. Of the desired product and purified by silica gel column chromatography (hexane / ethyl acetate = 80/10 vol / vol) to obtain the desired product, tert-butyl (R) -2-diphenylimino- (2-fluorophenyl) butyrate (405 mg, 1.05 mmol) was obtained as a colorless oil (yield:> 99%). In the measurement using a Daicel chiral column AD-H (hexane / isopropanol = 9/1 vol / vol), the optical purity was 98.5% ee.

実施例2〜実施例6 各種ハロゲン含有フェニルアラニン誘導体の調製
実施例1と同じ反応装置を用い、2−フルオロベンジルブロミドを表1に示したベンジルブロミドに替えた以外、実施例1と同じ操作を行い、各種ハロゲン含有フェニルアラニン誘導体を調製した。結果を表1中に示した。実施例4及び実施例6は1N−塩酸でイミノ基を脱離した後、ダイセル社製キラルカラムAD−H(ヘキサン/イソプロパノール=9/1 vol/vol)で光学純度を測定した。実施例5はダイセル社製キラルカラムOD−H(ヘキサン/イソプロパノール=9/1 vol/vol)で光学純度を測定した。これらの結果を表1に併せて示す。
Examples 2 to 6 Preparation of various halogen-containing phenylalanine derivatives The same operation as in Example 1 was performed except that 2-fluorobenzyl bromide was replaced with the benzyl bromide shown in Table 1 using the same reaction apparatus as in Example 1. Various halogen-containing phenylalanine derivatives were prepared. The results are shown in Table 1. In Examples 4 and 6, after removing the imino group with 1N-hydrochloric acid, the optical purity was measured with a chiral column AD-H (hexane / isopropanol = 9/1 vol / vol) manufactured by Daicel. In Example 5, optical purity was measured using a chiral column OD-H (hexane / isopropanol = 9/1 vol / vol) manufactured by Daicel Corporation. These results are also shown in Table 1.

Figure 2008007461
Figure 2008007461

実施例7
攪拌子を備えた50mlのナス型フラスコに、実施例1で得られたtert−ブチル (R)−2−ジフェニルイミノ−(2−フルオロフェニル)ブチレート(300mg,0.743mmol)、6N塩酸(10ml)及びエタノール(10ml)を入れ40℃で6時間反応を行った。反応終了後、重曹粉末で中和、蒸発乾固の後、エタノールを加え、ろ過、硫酸マグネシウム上で乾燥、ろ過、濃縮することにより目的物の(2−フルオロフェニル)アラニン(116mg、0.851mmol)を無色の固体として得た(収率85%)。
Example 7
In a 50 ml eggplant-shaped flask equipped with a stir bar, tert-butyl (R) -2-diphenylimino- (2-fluorophenyl) butyrate (300 mg, 0.743 mmol) obtained in Example 1 and 6N hydrochloric acid (10 ml) were added. ) And ethanol (10 ml) were added and reacted at 40 ° C. for 6 hours. After completion of the reaction, neutralization with sodium bicarbonate powder, evaporation to dryness, ethanol was added, filtration, drying over magnesium sulfate, filtration, and concentration to obtain the desired product (2-fluorophenyl) alanine (116 mg, 0.851 mmol). ) As a colorless solid (yield 85%).

Claims (4)

下記式(1)
Figure 2008007461
で示されるジフェニルイミノグリシン誘導体と、下記一般式(2)
Figure 2008007461
[上記一般式(2)中、Rはハロゲン原子、又はハロゲン原子で置換された炭素数1〜4の直鎖若しくは分岐のアルキル基を示す。]
で示されるベンジルブロミド誘導体を、下記式(3)
Figure 2008007461
で示されるキラル相間移動触媒及びアルカリの存在下反応させることを特徴とする下記一般式(4)
Figure 2008007461
[上記一般式(4)中、Rはハロゲン原子、又はハロゲン原子で置換された炭素数1〜4の直鎖若しくは分岐のアルキル基を示す。]
で示されるハロゲン含有フェニルアラニン誘導体の製造方法。
Following formula (1)
Figure 2008007461
And a diphenyliminoglycine derivative represented by the following general formula (2):
Figure 2008007461
[In the general formula (2), R represents a halogen atom or a linear or branched alkyl group having 1 to 4 carbon atoms substituted with a halogen atom. ]
A benzyl bromide derivative represented by the following formula (3)
Figure 2008007461
The reaction is carried out in the presence of a chiral phase transfer catalyst represented by the following general formula (4):
Figure 2008007461
[In the general formula (4), R represents a halogen atom or a linear or branched alkyl group having 1 to 4 carbon atoms substituted with a halogen atom. ]
The manufacturing method of the halogen-containing phenylalanine derivative shown by these.
請求項1に記載の式(1)で示されるジフェニルイミノグリシン誘導体と、請求項1に記載の一般式(2)で示されるベンジルブロミド誘導体を、下記式(5)
Figure 2008007461
で示されるキラル相間移動触媒及びアルカリの存在下反応させることを特徴とする一般式(6)
Figure 2008007461
[上記一般式(6)中、Rはハロゲン原子、又はハロゲン原子で置換された炭素数1〜4の直鎖若しくは分岐のアルキル基を示す。]
で示されるハロゲン含有フェニルアラニン誘導体の製造方法。
A diphenyliminoglycine derivative represented by the formula (1) according to claim 1 and a benzyl bromide derivative represented by the general formula (2) according to claim 1 are represented by the following formula (5):
Figure 2008007461
The reaction is carried out in the presence of a chiral phase transfer catalyst represented by the formula (6)
Figure 2008007461
[In the general formula (6), R represents a halogen atom or a linear or branched alkyl group having 1 to 4 carbon atoms substituted with a halogen atom. ]
The manufacturing method of the halogen-containing phenylalanine derivative shown by these.
請求項1に記載の一般式(4)で示されるハロゲン含有フェニルアラニン誘導体を酸の存在下、加水分解することを特徴とする下記一般式(7)
Figure 2008007461
[上記一般式(7)中、Rはハロゲン原子、又はハロゲン原子で置換された炭素数1〜4の直鎖若しくは分岐のアルキル基を示す。]
で示されるハロゲン含有フェニルアラニンの製造方法。
The halogen-containing phenylalanine derivative represented by the general formula (4) according to claim 1 is hydrolyzed in the presence of an acid, and the following general formula (7)
Figure 2008007461
[In the general formula (7), R represents a halogen atom or a linear or branched alkyl group having 1 to 4 carbon atoms substituted with a halogen atom. ]
The manufacturing method of halogen-containing phenylalanine shown by these.
請求項2に記載の一般式(6)で示されるハロゲン含有フェニルアラニン誘導体を酸で存在下、加水分解することを特徴とする下記一般式(8)
Figure 2008007461
[上記一般式(8)中、Rはハロゲン原子、又はハロゲン原子で置換された炭素数1〜4の直鎖若しくは分岐のアルキル基を示す。]
で示されるハロゲン含有フェニルアラニンの製造方法。
The halogen-containing phenylalanine derivative represented by the general formula (6) according to claim 2 is hydrolyzed in the presence of an acid, and the following general formula (8)
Figure 2008007461
[In the general formula (8), R represents a halogen atom or a linear or branched alkyl group having 1 to 4 carbon atoms substituted with a halogen atom. ]
The manufacturing method of halogen-containing phenylalanine shown by these.
JP2006179753A 2006-06-29 2006-06-29 Method for producing halogen-containing phenylalanine derivative Pending JP2008007461A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006179753A JP2008007461A (en) 2006-06-29 2006-06-29 Method for producing halogen-containing phenylalanine derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006179753A JP2008007461A (en) 2006-06-29 2006-06-29 Method for producing halogen-containing phenylalanine derivative

Publications (1)

Publication Number Publication Date
JP2008007461A true JP2008007461A (en) 2008-01-17

Family

ID=39065980

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006179753A Pending JP2008007461A (en) 2006-06-29 2006-06-29 Method for producing halogen-containing phenylalanine derivative

Country Status (1)

Country Link
JP (1) JP2008007461A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014126244A1 (en) * 2013-02-18 2014-08-21 長瀬産業株式会社 Method for producing amino acid and amino acid synthesis kit

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014126244A1 (en) * 2013-02-18 2014-08-21 長瀬産業株式会社 Method for producing amino acid and amino acid synthesis kit

Similar Documents

Publication Publication Date Title
RU2388753C2 (en) Method of obtaining intermediate product taking part in irbesartan synthesis
KR102608490B1 (en) Novel synthesis method of 1-aryl-1-trifluoromethylcyclopropane
KR100261361B1 (en) Process of optically active 2-halo-1-(substituted phenyl)ethanol and optically active substituted styrene oxide, and method of promoting the optical purity of production of optically active 2-halo-1-(substituted phenyl)ethanol produced by the process
CA2980071A1 (en) Method for preparation of (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile
JP2008007461A (en) Method for producing halogen-containing phenylalanine derivative
EP0612716B1 (en) Process for the preparation of an optically pure aminoalcohol
WO2011019066A1 (en) Method for producing optically active 1-amino-2-vinylcyclopropanecarboxylic acid ester
JP4728636B2 (en) Process for producing optically active amino acids
JP2021509685A (en) Process for preparing chrysaborol and its intermediates
WO2003051852A1 (en) Intermediate and process for producing optically active compound from the intermediate
JP2005023055A (en) New optically active amine
JP5673169B2 (en) Quaternary ammonium salt and method for producing cyclopropane compound using the same
JP4929938B2 (en) Process for producing optically active α-amino acid benzyl esters
JP4126921B2 (en) Process for producing optically active β-phenylalanine derivative
JP2000072728A (en) Production of optically active alpha-substituted-beta- aminoketone derivative
JP2003137835A (en) Method for producing (r)-3-hydroxy-3-(2-phenyl)hexanoic acid
CN108101741B (en) A kind of method for alkyne hydration/asymmetric hydrogenation in series to synthesize chiral alcohol
KR100856891B1 (en) Manufacturing method of sumatriptan
JP2737304B2 (en) Chiral ferrocene derivatives
JP2005247785A (en) Optically active 1-aryl-2-fluoro-substituted ethylamine and method for producing the same
WO2006030892A1 (en) Process for production of heterocyclic compounds
JPH09295962A (en) 2,2'-disubstituted-ethanesulfonic acid derivative and its salt
JP5456871B2 (en) Selective process for producing (+)-cis-sertraline
JP2002193901A (en) Optical resolution of (1S *, 4R *)-4-amino-2-cyclopentene-1-carboxylic acid esters
JPS5946234A (en) Preparation of optically active alcohol